These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28870097)

  • 21. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.
    Cao L; Diedrich JK; Kulp DW; Pauthner M; He L; Park SR; Sok D; Su CY; Delahunty CM; Menis S; Andrabi R; Guenaga J; Georgeson E; Kubitz M; Adachi Y; Burton DR; Schief WR; Yates JR; Paulson JC
    Nat Commun; 2017 Mar; 8():14954. PubMed ID: 28348411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility.
    Go EP; Irungu J; Zhang Y; Dalpathado DS; Liao HX; Sutherland LL; Alam SM; Haynes BF; Desaire H
    J Proteome Res; 2008 Apr; 7(4):1660-74. PubMed ID: 18330979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conformational States of a Soluble, Uncleaved HIV-1 Envelope Trimer.
    Liu Y; Pan J; Cai Y; Grigorieff N; Harrison SC; Chen B
    J Virol; 2017 May; 91(10):. PubMed ID: 28250125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.
    Verkerke HP; Williams JA; Guttman M; Simonich CA; Liang Y; Filipavicius M; Hu SL; Overbaugh J; Lee KK
    J Virol; 2016 Oct; 90(20):9471-82. PubMed ID: 27512064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.
    van den Kerkhof TL; de Taeye SW; Boeser-Nunnink BD; Burton DR; Kootstra NA; Schuitemaker H; Sanders RW; van Gils MJ
    Retrovirology; 2016 Jul; 13(1):48. PubMed ID: 27388013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens.
    Newby ML; Allen JD; Crispin M
    Biotechnol Adv; 2024; 70():108283. PubMed ID: 37972669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins.
    Jan M; Upadhyay C; Alcami Pertejo J; Hioe CE; Arora SK
    PLoS One; 2018; 13(3):e0194498. PubMed ID: 29579062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 envelope glycan moieties modulate HIV-1 transmission.
    Shen R; Raska M; Bimczok D; Novak J; Smith PD
    J Virol; 2014 Dec; 88(24):14258-67. PubMed ID: 25275130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.
    Liu CC; Zheng XJ; Ye XS
    ChemMedChem; 2016 Feb; 11(4):357-62. PubMed ID: 26762799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming Challenges in Structural Characterization of HIV-1 Envelope Glycoprotein by LC-MS/MS.
    Ivleva VB; Cooper JW; Arnold FJ; Lei QP
    J Am Soc Mass Spectrom; 2019 Sep; 30(9):1663-1678. PubMed ID: 31111416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.
    Phad GE; Vázquez Bernat N; Feng Y; Ingale J; Martinez Murillo PA; O'Dell S; Li Y; Mascola JR; Sundling C; Wyatt RT; Karlsson Hedestam GB
    J Immunol; 2015 Jun; 194(12):5903-14. PubMed ID: 25964491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
    Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 Envelope Glycosylation and the Signal Peptide.
    Lambert GS; Upadhyay C
    Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33669676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.